Elizabeth Parrish

Elizabeth Parrish is a researcher in the field of gene therapy. Her published work investigates gene therapy approaches for healthy life extension, including intranasal and injectable methods, as well as the assessment of biosimilar gene therapies.

22 claims checked on air: 2 context 1 contradicted 4 overstated 8 supported 7 unverified

What they said on air - context

0:10:05needs contextlowIs Aging a Disease? Inside the First Human Gene Therapy Expe

In 24 species, including humans, lifespan is tied to the rate of telomere shortening.

"In 24 species, including humans, lifespans are tied to that shortening." (said at 0:10:05)

Comparative studies examining telomere dynamics across diverse animal species and humans have shown that the rate of telomere shortening, rather than initial telomere length alone, strongly correlates with species lifespan. For example, Whittemore et al. (2019) measured longitudinal telomere shortening rates across various bird and mammalian species alongside human data, concluding that telomere shortening rate predicts species maximum lifespan. The claim captures the core scientific finding that species longevity correlates with telomere shortening rates, though the exact number of species and the causal universality across all taxa remain subjects of ongoing debate in evolutionary biology.

supports: Telomere shortening rate predicts species life span. (Proceedings of the National Academy of Sciences of the United States of America 2019) · cited 379x in the literature
"We found that the telomere shortening rate, but not the initial telomere length alone, is a powerful predictor of species life span. These results support the notion that critical telomere shortening and the consequent onset of telomeric DNA damage and cellular senescence are a general determinant of species life span." (abstract, results, passage verified)
pubmed full study (doi)

0:39:44needs contexthighIs Aging a Disease? Inside the First Human Gene Therapy Expe

An adenovirus gene therapy trial shut down the field of gene therapy in 1990 due to an adverse event.

"adenovirus which is a large virus and and it is the one that kind of shut down gene therapy in in 1990 due to an ill effect." (said at 0:39:44)

The claim is partially accurate regarding the cause and impact of the adverse event, but contains a significant error regarding the date. The landmark adenovirus gene therapy trial that caused severe immunotoxicity, resulted in a high-profile patient death, and halted/slowed clinical gene therapy research occurred in September 1999 (the trial for ornithine transcarbamylase deficiency led by the University of Pennsylvania, in which 18-year-old Jesse Gelsinger died), not in 1990. In 1990, the first approved human gene therapy trial took place (using a retroviral vector for adenosine deaminase deficiency in a four-year-old patient), which was successful and safe.

context: Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency (Molecular Genetics and Metabolism 2009) · cited 298x in the literature
"It has been 9 years since Mr. Jesse Gelsinger died from complications of vector administration in a liver gene therapy trial of research subjects with a deficiency of ornithine transcarbamylase (OTCD). This study was performed at the Institute for Human Gene Therapy of the University of Pennsylvania (Penn) which I directed. His tragic death provoked a series of events that had implications beyond those directly involved in the clinical trial." (abstract, passage verified)
openalex full study (doi)

Fact-checked episodes

Is Aging a Disease? Inside the First Human Gene Therapy Experiment | Elizabeth ParrishDavidPerlmutterMD · as guest

Publications

New intranasal and injectable gene therapy for healthy life extension.Proceedings of the National Academy of Sciences of the United States of America 2022 · CEBM Level 5
Biosimilar Gene Therapy: Investigational Assessment of Secukinumab Gene Therapy.Cell journal 2020 · CEBM Level 5